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disorder (OR 20.1: CI 12.3-33.1) significantly increased the use of antipsychotic 
medication in children with ADHD. CONCLUSIONS: Stimulants remained the 
mainstay of treatment for ADHD in children, although its use decreased after 
2006 which is consistent with other studies. Antipsychotic use was less common 
but increased significantly in recent years.  
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IMPACT OF POLYDRUG USE ON PRESCRIPTION DRUG ABUSE  
Parikh NS, Nayak R 
St. John's University, Jamaica, NY, USA  
OBJECTIVES: Prescription drug abuse has emerged as a major public health 
threat over the past decade. The role of polydrug use (PDU) of psychotherapeutic 
drugs is currently not well understood in prescription drug abuse (defined as 
nonmedical use of prescription drugs-NMUPD). This study aims to characterize 
NMUPD and examine the role of PDU in contributing to prescription drug abuse. 
METHODS: The National Survey of Drug Use and Health (NSDUH-2010) was 
utilized to study a population of noninstitutionalized, civilian Americans, aged 
12 years and over for NMUPD. NMUPD was defined as the act of consuming a 
drug from any of the four drug classes (pain relievers, stimulants, tranquilizers 
and sedatives) without a valid prescription or with a prescription for the 
experience or feeling it caused. PDU was defined as the use of two or more 
prescription psychotherapeutic drugs within the past one year. Associations 
between PDU and NMUPD were tested with respect to demographic and socio-
economic factors. RESULTS: Out of a sample of 5166 individuals who were taking 
psychotherapeutic drugs, about 29% (n=1493) were engaged in PDU. About 4.47% 
(n=231) of the sample fit the criteria for NMUPD. About 6.50% (n=97) of the PDU 
sample (n=1493) were engaged in NMUPD. NMUPD was found to be more 
common among polydrug-users than monodrug-users (6.5% vs. 3.65%). A Chi-
Square test for independence showed a significant association between PDU and 
NMUPD (χ2=20.167, p<0.0001). Demographically, a majority of the polydrug-users 
with NMUPD were in the age-group 18-25 years (55%), female (54.64%), single 
(83.51%), nonhispanic white (77.32%), with high school graduation (60.82%) and 
income less than $10,000 annually (68.04%). CONCLUSIONS: PDU is a notable and 
legitimate risk factor for NMUPD. NMUPD among polydrug-users appears to be 
more prevalent in a population that is young, mostly female, nonhispanic white, 
with limited income and education.  
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PREDICTORS OF USE OF ATYPICAL ANTIPSYCHOTICS AND LONG ACTING 
STIMULANTS POLYPHARMACY AMONG CHILDREN AND ADOLESCENTS  
WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER  
Bali V, Kamble P, Aparasu RR 
University of Houston, Houston, TX, USA  
OBJECTIVES: Psychotropic polypharmacy is common in pediatric Attention 
Deficit/Hyperactivity Disorder (ADHD). This study examined determinants of the 
long acting stimulant (LAS) and atypical antipsychotic (AAP) polypharmacy in 
children and adolescents with ADHD. METHODS: This study used 4 years 
(January 2004 to December 2007) of IMS LifeLink™ claims data involving 6-16 
years old children with ADHD and at least one LAS prescription between July 
2004 to December 2006 and continuous eligibility 6 months before and 1 years 
after the index LAS prescription. Polypharmacy was defined as the concurrent 
prescription for LASs and AAPs for at least 14 days within the 365 days after the 
index LAS claim. Multiple logistic regression analysis was performed to examine 
predictors of LASs and AAPs polypharmacy in pediatric ADHD. RESULTS: The 
study cohort consisted of 39,981 children and adolescents. Of these, 1,560 (3.90%) 
received LAS and AAP polypharmacy and the rest 38,421 (96.10%) received LAS 
monotherapy. Multivariate logistic regression analysis revealed that factors 
positively associated with psychotropic polypharmacy were: male, year of cohort 
entry (2005 and 2006), initiation of LAS in summer, psychiatrist visit, depression, 
conduct disorder, enuresis, tics, bipolar disorder, oppositional disruptive 
disorder, psychosis and pervasive developmental disorders, use of psychotropic 
medications from other drug class such as α2-agonists, antidepressants, mood 
stabilizers and other miscellaneous medications, and mental health-related 
hospital visit in the past 6 months. Children with public health insurance, those 
residing in Midwest and West regions, those who initiated use of index LAS in 
spring, those seen by pediatrician, and those with comorbidity of substance 
abuse and dependence were less likely to receive LAS and AAP polypharmacy. 
CONCLUSIONS: Various patient, clinical and treatment factors were associated 
with the receipt of polypharmacy among ADHD youths. Understanding of these 
factors can help to manage psychotropic polypharmacy and improve quality of 
care in pediatric ADHD.  
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OBJECTIVES: The study examined the prevalence and factors associated with 
concurrent use of long acting stimulants (LAS) and atypical antipsychotic agents 
among children and adolescents who initiated LAS medications for Attention 
Deficit/Hyperactivity Disorder (ADHD). METHODS: The study involved 
retrospective longitudinal analysis of 2003-2007 Medicaid Analytical eXtract 
(MAX) data of four US states. The study focused on children and adolescents 
aged 6 to 17 years, diagnosed with ADHD, and who initiated LAS from July 2003 
to December 2006. Concurrent use was defined as receipt of both medications 
together at least for 14 days. The study cohort was followed uniformly for one 
year after the initiation of LAS medications to examine the concurrent use. 
Descriptive analysis was conducted to examine the utilization pattern. Multiple 
logistic regression analysis within the conceptual framework of Andersen 
behavioral model was conducted to examine determinants of concurrent use 
with LAS use only as a reference group. RESULTS: Among the 61,793 children 
and adolescents who initiated ADHD treatment with LAS, 11, 866 (19.20%) 
received LAS and atypical antipsychotics concurrently. Risperidone was 
frequently used concurrently with LAS in children. The multiple logistic 
regression revealed that children and adolescents with male gender, black race, 
and foster care benefits were more likely to receive LAS and atypical 
antipsychotics concurrently than their counterparts. Moreover, FDA approved 
indications such as schizophrenia, bipolar disorder, and psychosis and non-
approved indications such as oppositional defiant disorder, pervasive 
developmental disorder, tic disorder, and personality disorder determined  
the concurrent use. CONCLUSIONS: Almost 1 in 5 children and adolescent 
received LAS and atypical antipsychotics concurrently. In addition to  
FDA approved indications, non-approved indications determined the concurrent 
use. There is urgent need to evaluate the safety and efficacy of concurrent use of 
LAS and atypical antipsychotics in children and adolescents for various 
indications.  
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PREVALENCE OF DEPRESSIVE SYMPTOMS AND PREDICTORS OF TREATMENT 
AMONG ADULTS FROM 2005 TO 2010 IN THE UNITED STATES  
Wittayanukorn S, Qian J, Hansen RA 
Auburn University, Auburn, AL, USA  
OBJECTIVES: Depression is a major public health concern with significant 
patient and societal burden. However, many patients with depressive symptoms 
do not receive treatment. This study examined nationally representative 
estimates of the prevalence of depressive symptoms and factors associated with 
treatment. METHODS: A cross-sectional, retrospective analysis of adults age ≥18 
represented in the 2005-2010 National Health and Nutrition Examination Survey 
(NHANES) data (n=15,838; weighted n=194,685,449) who responded to the Patient 
Health Questionnaire (PHQ-9) was conducted. Depressive symptoms were 
defined by PHQ-9 score ≥5. Depression treatment was defined as receiving either 
antidepressants or psychotherapy. Multivariate logistic regression analyses using 
population weights were performed to identify factors associated with having 
depressive symptoms. Among the group of patients with moderate to severe 
depression, similar models assessed factors associated with receipt of treatment. 
RESULTS: The prevalence of depressive symptoms increased gradually from 
2005-2010 (21.4% in 2005-2006; 25.6% in 2007-2008; and 26.1% in 2009-2010). 
Among patients with moderate to severe depressive symptoms, over one-third 
(weighted n=6,132,302; 37.0%) received either antidepressants or psychotherapy 
treatment. Multivariate results found that comorbidities (high blood pressure, 
diabetes, asthma, arthritis, heart failure, stroke, COPD, and obesity), previous 
hospitalization, having no health insurance, seeing a mental professional, 
receiving antipsychotic drugs, female, Hispanic ethnicity, in poverty status, and 
age of 20-59 (vs. age <20) were significant factors associated with having 
depressive symptoms (P<0.05). Among patients with moderate to severe 
depression, comorbidities (asthma and cancer), seeing a mental professional, 
receiving antipsychotic drugs, female, and Non-Hispanic White race were 
statistically significantly associated with receipt of treatment (P<0.05). 
CONCLUSIONS: Although the prevalence of depression symptoms is high and 
growing in the U.S. population, only a small portion of patients with moderate to 
severe depression received treatments. Additionally, significant disparities by 
ethnicity and use of mental professionals appear to be associated with the 
likelihood of receiving treatment.  
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Kamble P1, Aparasu RR1, Chen H1, Johnson ML1, Abughosh S1, Bhatara V2 
1University of Houston, Houston, TX, USA, 2University of South Dakota, Sioux Falls, SD, USA  
OBJECTIVES: To examine the impact of atypical antipsychotic use on the 
persistence of long acting simulants (LAS) in children and adolescents with 
Attention Deficit/Hyperactivity Disorder (ADHD). METHODS: The study involved 
retrospective longitudinal analysis of 2003-2007 Medicaid Analytical eXtract 
(MAX) data of four US states. The study focused on children and adolescents 
aged 6 to 17 years, diagnosed with ADHD, and who initiated LAS after 6 months 
washout period. Concurrent use was defined as receipt of both medications 
together at least for 14 days. The persistence of LAS was defined as number of 
days to discontinuation of index LAS. The patients were censored at the 
discontinuation of index LAS or end of study period whichever comes first. 
Descriptive analysis was used to examine demographic, service related, and 
clinical characteristics of study sample. Accelerated Failure Time (AFT) 
regression was conducted to examine the determinants of persistence of LAS. 
RESULTS: Among the 61,793 children and adolescents who initiated LAS for 
ADHD 9,902 (16.03%) received LAS and atypical antipsychotic concurrently. Most 
of the study sample was children aged between 6-12 years, males, and whites. 
The mean duration of LAS treatment was longer (200 days) among concurrent 
users than only LAS users (143 days). The AFT regression found that concurrent 
users had 45% longer (STR, 1.45; 95% CI, 1.41-1.49) LAS persistence than those 
using LAS only. Adolescents and non-whites had shorter LAS treatment 
persistence than their counterparts after controlling for demographics, service 
related, and clinical factors. CONCLUSIONS: The concurrent users had longer 
LAS treatment continuity than LAS only users. The addition of the atypical 
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antipsychotic agents to LAS treatment may be beneficial in improving treatment 
persistence in ADHD.  
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OBJECTIVES: As in many other developing countries of the world, mental health 
research in Ghana has received little attention. The epidemiology of the disease 
and the actual prevalence in the general population are virtually unknown. Few 
small scale studies have identified factors associated with depression in the 
country. Nonetheless, because of their limited scope, quality and scale of these 
studies, there remains a gap in knowledge regarding factors associated with 
depression in a general population. Therefore, the purpose of the study is to 
examine the prevalence of self-reported depression among adults (age > 18) and 
analyze the association between demographic, socio-economic, health 
conditions, and life-style practices and presence of depression in a West African 
country (Ghana) using 2002 World Health Survey. METHODS: Cross-sectional 
design was used. Data were extracted from the World Health Survey for the year 
2002. Based on an algorithm developed by Ayuso-Mateos and colleagues using 
World Health Survey, we combined depressive episode, brief episode and 
subsyndromal depression to measure presence of depression. Chi square 
statistics and logistic regressions were utilized to examine the relationship 
between self-reported depression and demographic, socio-economic, health 
conditions, and life-style practices in Ghana. RESULTS: Overall, 11.9% adults 
reported depression. Logistic regression on presence of depression revealed that 
women were more likely to have depression compared to men (AOR = 1.46, 95% 
CI = 1.13, 1.89). Among other factors, those with chronic conditions (arthritis and 
heart disease) were more likely to have depression compared to those without 
these conditions. CONCLUSIONS: This study confirms the gender differences in 
prevalence of depression. The relationship between chronic conditions and 
depression highlights the need for medical and behavioral treatment integration 
in Ghana.  
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Rajagopalan K1, Kleinman NL2, Brook RA3, Cape AP4, Smeeding JE5, Loebel A6 
1Sunovion Pharmaceuticals, Inc., Marlborough, MA, USA, 2The HCMS Group, Cheyenne, WY, 
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Objective: To predict the demographic, diagnostic, comorbid, and drug 
utilization factors that may impact the likelihood of subjects initiating 
lurasidone among US employers. Methods: Analyses of administrative claims 
data from the HCMS Database comprised of multiple large geographically 
dispersed US employers from 2/1/2011(lurasidone launch) through 9/30/2012. All 
continuously enrolled subjects with a schizophrenia or bipolar disorder 
diagnosis with a prescription claim of lurasidone were classified as lurasidone 
subjects; those without a lurasidone prescription claim were controls. 
Demographics, Charlson comorbidity index (CCI) score, specific bipolar disorder 
or schizophrenia diagnoses, and use of atypical antipsychotics were described 
using means for continuous variables and proportions for categorical variables. 
Factors predicting the likelihood of initiating lurasidone were evaluated using 
stepwise logistic regression. Results: From a total of 127 lurasidone subjects and 
7754 controls, 43 lurasidone subjects (1.1%) and 3822 control subjects were 
eligible for analysis with 40.4% employees, 31.2% spouses, and 28.4% 
dependents.  The employees/spouses were 67% female, mean age 44.1 (SD=10.8) 
years and mean CCI score of 0.72 (SD=1.42). Dependents were 49% female, with 
mean age 20.7 (SD=7.4) years and mean CCI score of 0.27 (SD=0.72). The most 
commonly used atypical antipsychotics were: aripiprazole=18.6%, 
quetiapine=18.3%, risperidone=11.6%, olanzapine=6.2%, and ziprasidone=5.7%. 
Logistic regression found subjects with schizoaffective disorder (ICD-9=295.7x, 
OR=3.6, P=0.0023); use of paliperidone (OR=7.8, P<0.0001), ziprasidone (OR=5.3, 
P<0.0001), or aripiprazole (OR=2.1, P=0.0233); and younger ages (OR=0.97, 
P=0.0244) were more likely to initiate lurasidone. Conclusion: This analysis 
suggests that subjects with schizoaffective disorder and paliperidone, 
ziprasidone, aripiprazole use were >2 times as likely to take lurasidone 
compared to controls. Additionally, younger subjects were more likely to take 
lurasidone.  
 
PMH19  
MENTAL COMORBIDITY AND IN-HOSPITAL MORTALITY AMONG PATIENTS 
WITH ACUTE MYOCARDIAL INFARCTION  
Sohn M, Moga DC, Talbert J 
University of Kentucky, Lexington, KY, USA  
OBJECTIVES: This study examines whether mental comorbidity affects in-
hospital mortality among individuals with acute myocardial infarction (AMI). 
The present study uses nationally representative data and provides insight for 
understanding the impact of mental comorbidity on in-hospital outcomes 
among individuals with AMI. METHODS: The Nationwide Inpatient Sample (NIS) 
database of the Health Care Cost and Utilization Project (HCUP) for 2010 was 
used to identify cases where the primary diagnoses at discharge was AMI (ICD-9-
CM; 410.XX). Mental comorbidity cases were identified as discharges with 1 or 
more mental disorders (ICD-9-CM; 290.XX-319.XX) listed as the non-primary 
diagnosis. The impact of mental comorbidities on in-hospital mortality was 
evaluated using Cox proportional hazards regression. RESULTS: A total of 
232,813 cases with AMI were included in the analysis. Of these, 112,327 (48%) had 
at least one diagnosis of a mental comorbidity. According to the Cox proportional 
hazards estimation result, the presence of mental comorbidity significantly 
increases the probability of having in-hospital death (Hazard Ratio: 1.34, 95% CI: 
1.23–1.46). CONCLUSIONS: Our results suggest that mental conditions could 
increase in-hospital mortality among individuals with AMI. Whether having 
mental comorbidities is per se a risk factor for in-hospital mortality post-AMI or 
is a proxy for other unmeasured factors needs further investigation. Regardless, 
our finding suggests that presence of mental comorbidities should be accounted 
for when treating patients.  
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OBESITY AND COMMON MENTAL HEALTH CONDITIONS: DEPRESSION  
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OBJECTIVES: This study examined, if presence of depression and/or anxiety 
confer additional risk for chronic physical conditions in the presence of obesity. 
METHODS: We used a retrospective cross-sectional study design. Study 
participants were 32,251 adults aged 22-64 years from 2007 and 2009 Medical 
Expenditure Panel Survey. Body mass index values (BMI) were used to classify 
sample adults into normal, overweight, and obese categories. Presence of 
depression and/or anxiety and BMI were combined to classify participants into 
six categories: 1) No depression and/anxiety and normal BMI;2) No depression 
and/anxiety and overweight; 3) No depression and/anxiety and obese; 4) 
Depression and/or anxiety and normal BMI; 5) Depression and/or anxiety and 
overweight; 6) Depression and/or anxiety and obese. Binary outcome variables 
indicating presence/absence of asthma, arthritis, diabetes, gastro esophageal 
reflux disease (GERD), chronic obstructive pulmonary disorder, hypertension, 
heart disease, osteoporosis, and thyroid disorders, were outcome measures. 
Exponentiated coefficients from two separate complementary log-log regressions 
were used to determine the risk of chronic physical conditions in presence 
obesity and depression and/anxiety. We tested the independent association of 
depression and/or anxiety with risk of chronic physical conditions by specifying 
two contrasts using the following reference groups ‘no depression and no 
anxiety with obesity’ and ‘no depression and no anxiety and normal BMI’ in two 
separate regression models. RESULTS: Among individuals with obesity, those 
with depression and/or anxiety were at higher risk of having chronic physical 
conditions (except osteoporosis) compared to individuals with no depression and 
no anxiety. The Adjusted Risk Ratios (ARRs) ranged from 2.07 (95% CI: 1.73, 2.48) 
for GERD to 1.29 (95%CI: 1.07, 1.56) for asthma. Among individuals with normal 
BMI, those with depression and/or anxiety were at higher risk of having chronic 
physical conditions compared to individuals with no depression and no anxiety. 
The ARRs ranged from 2.30 (95%CI: 1.69, 3.13) for GERD to 1.44 (95%CI: 1.22, 1.69) 
for arthritis. CONCLUSIONS: Presence of depression and/or anxiety conferred an 
independent risk for having chronic physical conditions after regardless of BMI 
categories.  
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BUDGET IMPACT ANALYSIS OF QUETIAPINE VERSUS ARIPIPRAZOLE OR 
OLANZAPINE ON THE TOP OF STANDARD THERAPY IN THE TREATMENT  
OF BIPOLAR DISORDER IN RUSSIAN FEDERATION  
Kulikov A, Komarov I 
I.M. Sechenov First Moscow State Medical University, Moscow, Russia  
OBJECTIVES: To estimate the budget impact of the inclusion of quetiapine 
compared to aripiprazole or olanzapine on the top of standard bipolar disorder 
treatment scheme with atypical antipsychotics according to Russian health care 
system. METHODS: The one year budget impact analysis was conducted. Direct 
expenses associated with bipolar disorder and resulting follow-up costs were 
calculated using general tariff agreement of Russian obligatory insurance system 
and official national statistics. For reference, accepted exchange rate was 1 EUR = 
40 RUB. RESULTS: Quetiapine inclusion into the standard bipolar disorder 
therapy provided cost saving benefits compared with inclusion of aripiprazole or 
olanzapine in the bipolar disorder standard therapy scheme. Total health care 
costs of bipolar disorder therapy were approximately 396 539 RUB (9,913 EUR) per 
patient in quetiapine group, 1,023 089 RUB (25,577 EUR) per patient in 
aripiprazole group and 557,222 RUB (13,931 EUR) per patient in olanzapine group 
within one year. Treatment of bipolar disorder using standard therapy with 
quetiapine inclusion compared to one with aripiprazole or olanzapine leads to 
cost savings of 626,551 RUB (15,664 EUR) or 160,683 RUB (4,017 EUR) per patient-
year, respectively. CONCLUSIONS: The results of budget impact analysis 
illustrate that including quetiapine into the standard therapy of bipolar disorder 
in comparison with aripiprazole or olanzapine has potential to reduce Russian 
health care system total costs for bipolar disorder treatment.  
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